Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. Peloton is initially targeting HIF-2α, a transcription factor which was previously thought to be intractable using a small molecule. The company is a leader in the field of HIF-2α biology and pioneered the first HIF-2α to enter into clinical development.

Translating Novel Scientific Insights Into First-In-Class Medicines

Peloton has opportunities to completely transform established treatment paradigms and improve patient outcomes in kidney cancer, VHL Disease, and other serious diseases.

Our drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches.

ABOUT US

Leadership

Board of Directors

Scientific Advisory Board

Investors

OUR SCIENCE

HIF-2α

CD73

Ubiquitin Ligase

PIPELINE

HIF-2α Development Program

Clinical Trials

Publications

Expanded Access Policy

NEWSROOM

Archives 2017

Archives 2016

Media Contact

CONTACT

Business Development

Privacy

CAREERS

Job Listings

Dallas Life

San Francisco Life

2330 Inwood Rd Suite 226,
Dallas, TX 75235

+1 (972) 629-4100

 

580 California St  Suite 1658, 16th Floor
San Francisco, CA  94104

© 2020 Peloton Therapeutics, Inc. All rights reserved.

Legal  |  Cookies